
Jonathan Kolitz JONATHAN KOLITZ, Monter Cancer Center, Lake Success, NY GEORGE CANELLOS, Dana-Farber Cancer Institute For patients with acute myeloid leukemia in first remission, new data suggests tha

Terry Gernsheimer TERRY GERNSHEIMER, University of Washington Medical Center, Seattle An investigational drug AMG 531 has increased and sustained platelet counts in splenectomized patients with chroni

Zakari Aliyu REFERENCE: American Society of Hematology Annual Meeting, December 8-11 2007, Atlanta ZAKARI ALIYU, Howard University, Washington DC Nigeria has the highest incidence of sickle cell anemi

Bengt Eriksson REFERENCE: Abstract 6, American Society of Hematology Annual Meeting, December 8-11 2007, Atlanta BENGT ERIKSSON, Gothenburg University In a large phase III trial of patients having a h

Jean-Yves Douillard Gordon McVie REFERENCE: Abstracts: 6507 & 2LB, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007 JEAN-YVES DOUILLARD, Centre René Gauducheau, N

George Sopko

Ernst Rietzschel Jennifer Mieres REFERENCE: News Briefing, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida N Engl J Med 2007;357 ERNST RIETZSCHEL, University of Gh

Gregg Stone REFERENCE: Abstract 2357, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida GREGG STONE, Columbia University, New York New light has been thrown on the u

Philip Barter Gordon Tomaselli REFERENCE: Late Breaking Clinical Trials, Session 2, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida N Engl J Med 2007;357 PHILIP BA

Ake Hjalmarson Gordon Tomaselli REFERENCE: Late Breaking Clinical Trials, Session 2, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida N Engl J Med 2007;357 AKE HJAL

Uwe Zeymer REFERENCE: Late Breaking Clinical Trials Session I, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida UWE ZEYMER, Herzzentrum Ludwigshafen, Germany The gl

Gordon Tomaselli Daniel Jones REFERENCE: Late Breaking Clinical Trials 1, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida GORDON TOMASELLI, Johns Hopkins Universit